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Viruses are among the most common causes of opportunistic infection after transplantation. The risk for viral infection is a func-
tion of the speciﬁc virus encountered, the intensity of immune suppression used to prevent graft rejection, and other host factors
governing susceptibility. Although cytomegalovirus is the most common opportunistic pathogen seen in transplant recipients,
numerous other viruses have also aﬀected outcomes. In some cases, preventive measures such as pretransplant screening,
prophylactic antiviral therapy, or posttransplant viral monitoring may limit the impact of these infections. Recent advances in
laboratory monitoring and antiviral therapy have improved outcomes. Studies of viral latency, reactivation, and the cellular eﬀects
of viral infection will provide clues for future strategies in prevention and treatment of viral infections. This paper will summarize
the major viral infections seen following transplant and discuss strategies for prevention and management of these potential
pathogens.
1.Introduction
Solid organ transplantation is a therapeutic option for many
human diseases. Liver, kidney, heart, and lung transplanta-
tions have become standard therapy for selected end-stage
diseases. However, complications such as infection and allo-
graft rejection, which are related by immunosuppressive
therapy,remainmajorcausesofmorbidityandmortalityfol-
lowing solid organ transplantation. Epidemiologically, some
viral infections are the result of community exposures (in-
ﬂuenza, adenovirus), whereas some are commonly transmit-
ted with the allograft (cytomegalovirus, Epstein-Barr virus),
and others are the result of more distant exposures reacti-
vated in the setting of immune suppression (chicken pox
andvaricellazosterasshingles)[1–3].Multiplesimultaneous
infections, viral and nonviral, are also common, such as
cytomegalovirus (CMV) and human herpes virus 6 or cyto-
megalovirus and pneumocystis [3–6].
The eﬀects of viral infection are classiﬁed as direct and
indirect. Fever and neutropenia syndrome and invasive dis-
easesuchaspneumonia,enteritis,meningitis, orencephalitis
areconsidereddirecteﬀects.Indirecteﬀectsareduetorelease
of cytokines, chemokines, and growth factors in response to
viral infection of the body, which deepen immunosuppres-
sionandincreaseriskofotheropportunistic infections[2,7–
10]. In addition, viral infection may alter expression of sur-
face antigens (e.g., histocompatibility antigens), provoking
graft rejection and/or causing dysregulated cellular prolifer-
ation (contributing to oncogenesis). Multiple observational
studies implicate infection with HHV 6 and/or HHV 7 as
risk factors for CMV disease and CMV infection may trigger
HHV 6 and HHV 7 reactivation [3–5, 11, 12]. Recently,
coinfection of polyoma virus and CMV has been reported
in kidney transplant recipients. Polyoma virus may induce
CMV gene expression by stimulating cellular regulator pro-
teinsorbyitsowngeneregulatorproteins[13–15].Increased
viral replication and persistence may contribute to allograft
injury (ﬁbrosis) or chronic rejection. Virus-speciﬁc T cells
cross-reactive with allo-antigens can alter the memory allo-
speciﬁc T cell pool and may modulate allograft survival and
transplantation tolerance. Viral infection can also lead to the
generation of cross-reactive T cells directed against shared
antigens between virus and graft (“molecular mimicry”),
or neoantigens generated by viral expression within the
allograft environment [16–19].2 The Scientiﬁc World Journal
Many viral infections after renal transplantation result
from reactivation of “latent” viral infection in the host or
from the graft. Whether the virus “awakes” depends on the
nature of the virus, the tissue infected, and host immune res-
ponse. Some latent viruses are metabolically inactive, where-
as others are constantly replicating at low levels determined
by the eﬀectiveness of the host’s immune response. Multiple
factors contribute to viral activation after transplantation,
including immune suppression(especiallyreductionofcyto-
toxic immunity), graft rejection therapy, inﬂammation (cy-
tokines), and tissue injury. The host response is also less
eﬀective because of the mismatch in major histocompati-
bility antigens between the organ donor and host, which
reduces the eﬃcacy of direct pathway antiviral cellular im-
mune responses. These factors render the allograft suscepti-
ble to invasive viral infection.
The optimal approach to infection in the solid organ
transplantrecipientisprevention;failingthis,itspromptand
aggressive diagnosis and therapy are essential. The sources of
infectious agents after transplantation include endogenous
organisms, the allograft itself, and the environment. An im-
portant principle to consider when evaluating solid-organ
transplant recipients (and other immunocompromised
hosts) for infection is that the usual inﬂammatory response
to an infectious organism may be attenuated due to immu-
nosuppressive therapy and that therefore the signs and sym-
ptoms of infections may be blunted and diagnostic tech-
niques may be compromised [1, 20].
Pretransplant screening of potential organ donors and
recipients is an essential part of solid organ transplantation.
Several guidelines for pretransplant screening have been
published recently, including a consensus conference on
the immunocompromised patient, the American Society for
Transplantationclinicalpracticeguidelinesontheevaluation
of renal transplant candidates, and the American Society of
Transplant Physicians clinical practice guidelines on the eva-
luation of living renal transplant donors. Pretransplant
screening of the donor and recipient aﬀords an opportunity
to assess the safety of transplantation, to determine the pro-
phylaxis and preventive strategies utilized after transplant, to
detect and fully treat active infection in the potential reci-
pient prior to transplant, to update the vaccination status of
the potential recipient, and to educate the patient and family
about preventive measures [21, 22].
The generosity and altruism of organ donation have
no nationality and no frontiers. Due to this, increases in
migration and international travel have also led to a rise
in the number of donors from foreign countries. Linked to
this is an increased risk of infections from speciﬁc areas of
the world, which may persist in a latent or chronic form in
the donor and may be transmitted during transplantation.
Future advances will likely include the increasing use of
rapid molecular diagnostic testing, based on genomics, pro-
teomics, and metabolomics (the high-throughput measure-
ment and analysis of metabolites) and possibly additional
testing for emerging pathogen [23–26]. This paper focusses
on acute and recurrent viral infections that occur after adult
renal transplantation (Table 1).
2. Cytomegalovirus
Human cytomegalovirus-human herpesvirus 5 (CMV) be-
longs to order Herpesvirales, family Herpesviridae, sub-
family betaherpesvirinae, genus Cytomegalovirus, species
Human herpesvirus 5 [27]. Symptomatic CMV infection
occurs in 20 to 60% of all transplant recipients and is a signi-
ﬁcant cause of increased morbidity and mortality in this
population [28, 29]. When compared with other organ
transplant recipients, renal transplant patients are at lower
risk for CMV, in part due to the lower burden of latent
virus in the renal allograft. The incidence of CMV in the
renal transplant population is estimated to be between 8 and
32 percent [1, 9]. In the renal transplant population, infec-
tion can occur acutely or as reactivation of latent virus. In
the absence of prophylaxis, acute infection is most likely to
occur between the ﬁrst and third months following trans-
plant, when immune suppression is at its maximum. How-
ever, the onset of acute infection has been delayed by the use
of prophylactic antivirals in the early posttransplant period;
currently CMV typically occurs after the cessation of antivi-
ral prophylaxis, later in the ﬁrst year [20, 30]. CMV may
be transmitted to transplant recipients via infected donor
organs or cellular blood products. Three major patterns of
CMV transmission are observed in solid organ transplanta-
tion recipients: (1) primary infection develops when a CMV-
seronegative individual receives cells latently infected with
the virus from a seropositive donor, (2) secondary infection
or reactivation infection develops when endogenous latent
virus is reactivated in a CMV-seropositive individual post-
transplantation, and (3) superinfection or reinfection occurs
when a seropositive recipient receives latently infected cells
from a seropositive donor and the virus that reactivates post-
transplantation is of donor origin [1]. The seronegative
recipient of an organ from a seropositive donor is at highest
risk (without prophylaxis CMV infections hve been reported
to occur in 65–88% recipients, 48–60% of wich develop
CMV disease) [9, 28, 29].
Studies of the eﬀects of CMV disease or asymptomatic
infection on graft function and the risk of acute rejection
have had conﬂict results. Some studies have shown an asso-
ciation of CMV disease or CMV infection with an increased
graft loss [31, 32], while others failed to shown this eﬀect
[33, 34]. Sagedal et al. showed that both CMV disease and
surprisingly, even asymptomatic CMV infection were inde-
pendent risk factors for overall mortality beyond 100 days
posttransplantation and reduced graft survival [35]. On a
pathological level, CMV can replicate in the kidney tissues
and cause acute allograft dysfunction which usually im-
proveswithganciclovirtreatmentandreductionofimmuno-
suppression [36, 37]. Infection with CMV has also been im-
plicated in chronic allograft nephropathy which is the major
reason for the loss of renal allografts after the ﬁrst year
after transplantation [38]. CMV disease has been linked to
chronic rejection with arterial myointimal thickening, simi-
lar to atherosclerotic coronary disease [28, 39]. However, it
is still unclear whether the virus itself leads directly to this
glomerulonephropathy.The Scientiﬁc World Journal 3
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The presentation of CMV may be variable, ranging from
asymptomatic infection (as deﬁned by the presence of active
viral replication) to end organ or disseminated involvement.
Commonly patients present with symptoms of fever and
malaise sometimes associated with leukopenia, thrombo-
cytopenia, gastroenteritis, pneumonitis, hepatitis, or more
rarely retinal or central nervous system involvement [30].
T h et y p eo fi m m u n o s u p p r e s s i o nc a na ﬀect the presentation
a n ds e v e r i t yo fi l l n e s s[ 40, 41].
2.1. CMV Prevention. Serologic screening for antibody to
CMV should be performed on both donor and recipient
before transplant to identify patients at risk for after trans-
plant infection who might beneﬁt from preventive strategies
[23].TwostrategiesarecommonlyusedforCMVprevention:
(1) universal prophylaxis and (2) preemptive therapy. Uni-
versal prophylaxis involves giving antiviral therapy to all “at-
risk” patients beginning at or immediately after transplant
for a deﬁned time period. In preemptive therapy, patients
are monitored at regular intervals for early evidence of CMV
replication prior to the onset of clinical symptoms by use of
a laboratory assay [42]. Patients with early replication are
then treated with antiviral therapy to prevent symptomatic
disease. Each approach has advantages and disadvantages
that must be considered in the context of the patient and
the allograft [43]. Preemptive therapy may decrease drug
costs and toxicity. However, it requires excellent logistic
coordination in order to obtain, receive, and act on results
in a timely fashion; this can be diﬃcult if patients live quite
some distance from the transplant center. Prophylaxis might
have the theoretical advantage of preventing reactivation of
other viruses such as HHV 6, and theoretically may be more
likely to prevent indirect eﬀects of CMV. CMV resistance has
been observed with both strategies. Drugs that have been
evaluated for universal prophylaxis include acyclovir, gan-
ciclovir, valacyclovir, valganciclovir, and immune globulin
preparations. Based on current data, the optimal preemptive
strategy is unknown. Preemptive therapy is well suited for
transplant recipients at low or intermediate risk of CMV
disease, while prophylaxis may be better suited for those at
high risk [44, 45]. Some studies have concluded that pre-
emptive valganciclovir therapy and valacyclovir prophylaxis
are equally eﬀective in the prevention of CMV disease after
renal transplantation and there was no diﬀerence in overall
costs [46, 47]. Same conclusions were obtained in studies
that used the ganciclovir as antiviral therapy [48]. A meta-
analysis of 32 trials (3737 patients) performed to compare
outcomes for various prophylactic antivirals for transplant
patients at risk for CMV disease demonstrated that prophy-
laxis decreased CMV disease, CMV infection, and all-cause
mortality [49]. This meta-analysis showed that ganciclovir
wasmoreeﬀectivethanacyclovirinpreventingCMVdisease.
Valganciclovir and intravenous ganciclovir were found to
be as eﬀective as oral ganciclovir for prophylaxis. However,
the use of ganciclovir may be associated with a greater rate
of CMV resistance when compared with valganciclovir, at
least in the highest risk recipients [50, 51]. The length of
prophylactic treatment varies by institution, but generally
lasts for a minimum of 3 months.
2.2.CMVDiagnosis. Manytechniquesarecurrentlyavailable
to aid in the diagnosis of CMV disease. These include serol-
ogy, viral culture, shell vial culture, pp65 antigenemia test,
and qualitative and quantitative nucleic acid detection assays
[52]. Although histopathologic diagnosis remains the gold
standard, noninvasive measures of viremia are used more
commonly to determine the presence or absence of CMV.
The antigenemia assay (detection of lower matrix phospho-
protein pp65 in leukocytes) and nucleic acid testing includ-
ing CMV-PCR and hybrid-capture DNA are typically used
with the choice of methodology varying among centers [20,
28]. A clinically useful test should ideally have good sen-
sitivity and speciﬁcity, be able to detect asymptomatic CMV
infection and predict CMV disease thus helping in treatment
decisions, and be technically easy to perform. Although gen-
erally accepted as the most sensitive methodology for CMV
detection,nucleicacidtestinghasnotbeenwell-standardized
and recent studies have demonstrated substantial interlab-
oratory variability [53, 54]. Quantitative CMV assays have
two prominent gaps: neurologic disease, including choriore-
tinitis, and gastrointestinal disease, including invasive colitis
and gastritis. In these syndromes, the CMV assays are often
negative and invasive (biopsy) diagnoses are often necessary.
The schedule for screening should be linked to the in-
dividual’s risk for infection. In the patient being treated for
CMV infection, the assays provide an endpoint (a negative
assay) for therapy and the reinitiation of prophylaxis. In
the patient at high risk after the completion of prophylaxis,
weekly to biweekly screening should be considered to assure
the absence of infection for 3 to 6 months [2].
2.3. CMV Therapy. Treatment of active CMV disease re-
quires a combination of immunomodulation, antiviral ther-
apy, and reduction of immunosuppression, if possible [30].
The standard of care for treating CMV disease is 2 to 3
weeks of intravenous ganciclovir (5mg/kg twice daily, dose
adjustments for renal dysfunction) with demonstration of
clinicalandvirologicalresponsestotherapy[30].Incontrast,
oralganciclovirshouldnotbeusedforthetreatmentofCMV
disease because of the limited absorption and poor bioavail-
ability. In seronegative patients and those slow to respond
to therapy, the addition of CMV hyperimmune globulin
(100 to 150mg/kg per dose intravenously, given month-
ly) may be useful [2]. More recently, the introduction of
valganciclovir has allowed for the oral treatment of CMV
disease in SOT recipients. In a trial of 21 renal transplant
recipients with symptomatic CMV disease and viremia who
were treated with valganciclovir, all cleared their infection
and none experienced relapse during a mean follow-up of
5.5 months [55]. Recently, a multicenter randomized con-
trol trial was performed with 321 solid organ transplant
recipients which demonstrated oral valganciclovir was not
inferior to intravenously ganciclovir for the initial treatment
of CMV viremia [56]. Indeed, valganciclovir was recently
shown to be as eﬀective as intravenous ganciclovir in the
treatment of mild-to-moderate (i.e., nonsevere) CMV dis-
ease [57]. The duration of treatment for CMV disease should
be individualized and guided by virological and clinical
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to discontinuation of therapy in order to reduce the risk of
clinical relapse. Previous studies have shown that persistent
viraemia at the end of therapy is associated with a higher risk
of disease relapse [58]. Alternative therapies (not Food and
Drug Administration-approved for use in solid organ trans-
plant recipients) include foscarnet, cidofovir, and leﬂuno-
mide; these are reserved for treatment of antiviral resistance.
Foscarnet is active against most ganciclovir-resistant strains
of CMV but has neurotoxicity and renal toxicity with severe
magnesium wasting. Cidofovir has been used in renal trans-
plant recipients, however often with nephrotoxicity. Both
foscarnet and cidofovir may exhibit synergistic nephrotoxi-
city with calcineurin inhibitors [2]. One of the biggest chal-
lenges regarding the treatment of CMV is the emergence
of antiviral resistance. Although this is more commonly
noted in lung and pancreas transplant recipients, CMV re-
sistance to ganciclovir has been observed in renal transplant
recipients. Ganciclovir resistance should be suspected when
patients have persistent, unchanged viremia and/or symp-
toms at 2 weeks into therapy and in such cases, genotypic
assays for the detection of the mutations associated with
antiviral resistance should be performed. Treatment of resis-
tant isolates may include the use of foscarnet with or without
ganciclovir, or cidofovir [30] .S m a l lc a s es t u d i e sh a v ed e -
monstrated some eﬃcacy of leﬂunomide to treat CMV
disease in renal transplant patients. A prospective study of
17 patients treated with leﬂunomide for CMV demonstrated
viral clearance and healing of infected organs in 15 patients
(88%) [58]. Other potential therapeutic agents for multi-
drug-resistant CMV include immunoglobulins, leﬂunomide
and artesunate although data supporting their use remains
anecdotal [59–61]. Hence, there is a need to identify novel
agents and strategies for the management of CMV infection
and disease.
3. Herpes Simplex Virus
Human herpesvirus 1-herpes simplex virus 1 (HSV) be-
longs to subfamily Alphaherpesvirinae, genus Simplexvirus,
species Human herpesvirus 1. Seroprevalence for HSV-1 in
the adult population is 60%, while the incidence of HSV in
renal transplant recipients is estimated to be approximately
53% [1, 30]. HSV most commonly causes reactivation infec-
tionbutmaycauseprimaryinfection,transmittedbyperson-
to-person contact or via the allograft. Following primary
infection, the virus remains latent in the sensory nerve gan-
glia. In the absence of prophylaxis, HSV may be seen early,
in the ﬁrst posttransplant month. Reactivation or primary
HSV infection results in oral or genital mucocutaneous
lesions, occasionally causes pneumonitis, tracheobronchitis,
esophagitis, hepatitis, or disseminated infection [1, 30].
Disease may be more severe, invasive, and prolonged in
transplant recipients. HSV esophagitis may present with
superﬁcial, punched-out lesions that may be superinfected
withCandida.HSVisthemostcommonformofencephalitis
in transplant recipients. HSV PCR and cultures from cere-
brospinal ﬂuid can assist diagnosis. Diﬀuse interstitial pneu-
monitis may complicate disseminated disease. Multivisceral
involvement with HSV infection is often fatal [62–64].
Diagnosis may be made with the aid of direct ﬂuores-
cence antibody for HSV from vesicular lesions or PCR from
cerebrospinal ﬂuid or visceral tissue samples. Due to high
seroprevalence in the adult population, serologies are rarely
helpful in the setting of active infection [20].
Treatment of HSV infection with acyclovir has been
shown to be eﬀective. Mucocutaneous HSV infection in
solid-organ transplant recipients should be treated with oral
acyclovir while disseminated or deep HSV infection should
alwaysbetreatedwithintravenousacyclovir[1,30].Thedose
should be adjusted in patients with renal failure. Although
more toxic than acyclovir, ganciclovir and foscarnet are also
eﬀective against HSV. A concern with respect to chronic
acyclovir use is the development of resistant mutants of
HSV. Acyclovir resistance may arise from mutations in the
genes for thymidine kinase or DNA polymerase. Acyclovir
resistancehasbeenrarelyreportedinsomestrains;foscarnet,
cidofovir, and topical triﬂuridine may be considered for
treatment of resistant virus, although careful monitoring of
renal function is required [1, 2, 20, 65].
4.VaricellaZosterVirus
Human herpesvirus3-Varicella zoster(VZV) belongs to sub-
family Alphaherpesvirinae, genus Varicellovirus, species Hu-
man herpesvirus 3. VZV causes two distinct clinical diseases
following transplantation. Ninety percent of adult solid-
organ transplant recipients are VZV seropositive pretrans-
plantation, and thus VZV reactivation in this group will
cause herpes zoster. The remaining 10% are VZV seroneg-
ative and are thus at risk of primary infection. The incidence
of VZV in renal transplant recipients is lower than HSV
and is approximately 4 to 12% [1]. VZV causes a spectrum
of disease in solid organ transplant recipients, ranging
from localized dermatomal zoster (involving a few adjoining
dermatomes) to multidermatomal or disseminated zoster
withorwithoutvisceralinvolvement.Inacohortof869adult
solid organ transplants (434 renal transplant recipients),
7.4%oftherenaltransplantrecipientshadherpeszosterwith
a median time to onset of 9 month [66]. The main com-
plications of a VZV infection in this immunosuppressed
population were disseminated intravascular coagulation
(DIC) and hepatitis in almost half and pneumonitis in 29%
of patients. Infections of the allograft and of the CNS as well
as pancreatitis were also described. Concomitant bacterial or
CMV infections have been reported too [67].
Unilateral vesicular lesions in a dermatomal pattern are
usually suﬃciently characteristic of herpes zoster to enable a
clinical diagnosis; however, culture of VZV in susceptible cell
culture lines, demonstration of multinucleated giant cells on
Tzanck smear, and/or direct immunoﬂuorescence is recom-
mended for conﬁrmation. These techniques can also be used
for diagnosis in cases of primary infection [1]. Pretransplant
screening for previous VZV infection should be performed
and na¨ ıve patients should be vaccinated with live attenuated
varicella vaccine before transplant whenever possible to
avoid primary VZV infection after transplantation, an often
severe disease with a high mortality rate [67]. However, due
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should not be given it if transplant is expected within four
to six weeks to prevent active viral shedding at the time
of transplant [30]. A VZV na¨ ıve transplant patient who is
exposed to someone infected with varicella should receive
varicella immune globulin within 96 hours of exposure (if
available). If VZIG is not available, or the patient presents
greater than 96 hours following exposure, acyclovir may be
consideredforpostexposureprophylaxis[30].Posttransplant
prophylaxis against reactivation of VZV and also HSV is
recommended to prevent severe recurrences and consists
of ganciclovir in patients needing CMV prophylaxis. Those
patients who do not require CMV prophylaxis can receive
valacyclovir or acyclovir for approximately one to three
months posttransplant [30]. After transplantation, most au-
thorities defer vaccination with live vaccines; killed vaccine
appears to be beneﬁcial [67, 68]. VZ-immunoglobulin is rec-
ommended for immunocompromised individuals with ex-
posures to varicella or zoster; protection is incomplete [69].
5.Epstein-BarrVirus
Epstein-Barr virus-Human herpesvirus 4 (EBV) belongs to
subfamily Gammaherpesvirinae, genus Lymphocryptovirus,
s p e c i e sH u m a nh e r p e s v i r u s4 .I tc a ni n f e c tBl y m p h o c y t e sa s
wellasmalignantcellsofseverallineages,includingTlymph-
ocytes, epithelial cells, and smooth muscle cells. EBV is asso-
ciated with a wide range of malignancies, including post-
transplant lymphoproliferative disorder (PTLD), Hodgkin
and non-Hodgkin lymphomas, nasopharyngeal carcinoma,
gastric carcinoma, and leiomyosarcoma [70]. Nearly every
human is infected before adulthood. Infection early in child-
hood is usually asymptomatic, while delayed primary infec-
tion is typically manifested through the symptoms of infec-
tious mononucleosis. Once infection occurs, the viral geno-
meismaintainedforlifeinasmallfractionofBlymphocytes.
In the setting of allogeneic transplantation when iatrogenic
immunosuppression is used to prevent graft rejection, an
unintended consequence is failure to suppress active EBV
infection, which is accompanied by a heightened risk of de-
veloping PTLD [71]. PTLD is a potentially life-threatening
neoplasm exhibiting a spectrum of histopathologies ranging
from reactive-appearing, polyclonal lymphoid inﬁltrates to
sheets of undiﬀerentiated cells that are morphologically in-
distinguishable from malignant lymphoma or plasma cell
myeloma [70].
The majority of symptomatic infections in renal trans-
plant recipients are primary infection, likely related to reac-
tivation of donor virus. Since ninety percent of adults have
antibodies to EBV by age 40, symptomatic infection is most
commonly seen in pediatric populations. Renal transplants
have the lowest risk of acquiring PTLD in comparison with
othertransplantpopulations(approximately1to3%).PTLD
most commonly occurs in the ﬁrst year after transplant
[20, 30]. Symptoms are often quite nonspeciﬁc, for example,
fever, malaise, and anorexia, and some patients are asymp-
tomatic. PTLD frequently presents as a rapidly enlarging
massinthegraftedorgan,inlymphnodes,ﬁllingthemarrow
space, or in extranodal sites such as upper airway or intestine
[72].
Nearly all transplant recipients are infected or eventually
become infected by EBV, yet only a fraction will develop
PTLD. Risk factors for PTLD are as follows: EBV seronega-
tivity at the time of transplant, active primary EBV infection
at the time of transplant, underlying disease leading to trans-
plantation, prior splenectomy, second transplant, patient age
(children and older adults), coinfection by cytomegalovirus
and other viruses, acute or chronic graft-versus-host disease,
immunosuppressive drug regimen and intensity, cytokine
polymorphisms, HLA type and extent of HLA mismatch,
or the presence of multiple risk factors [70]. Active primary
EBV infection is a contraindication to transplantation [73].
The type of immunosuppression can alter the risk of devel-
opment of PTLD, with higher incidence rates observed in
patients receiving cytolytic therapies, including antithymo-
cyteglobulinandOKT3[74].Fludarabine,azathioprine,and
other agents causing profound T-cell suppression or muta-
genicity are also implicated in PTLD pathogenesis [75, 76].
PTLD is divided into four major histopathologic sub-
types with corresponding clinical and biologic features, as
described in the World Health Organization (WHO) sub-
classiﬁcation scheme [77]. These include early lesions, poly-
morphic PTLD, monomorphic PTLD, and classical Hodgkin
lymphoma type PTLD. Although these lesions may bear
microscopic resemblance to diseases arising sporadically in
otherwise healthy individuals (e.g., infectious mononucleo-
sis, diﬀuse large B-cell lymphoma, myeloma, Hodgkin lym-
phoma,andage-relatedB-celllymphoproliferativedisorder),
their occurrence in the setting of transplantation warrants a
diagnosis of PTLD given that the natural history and recom-
mended therapy for PTLD diﬀer from those for lesions hav-
ing similar histologic features in nonimmunocompromised
hosts. In terms of natural history, PTLD almost always pro-
gresses quite rapidly to a fatal conclusion unless promptly re-
cognized and treated [70]. The ability to reduce or eliminate
immunosuppressive drugs is a helpful strategy for restoring
natural antiviral and antineoplastic immunity.
Biopsy is necessary to conﬁrm a diagnosis of PTLD
and to rule out other neoplastic or infectious lesions [73].
Histochemical stains are helpful in narrowing the diﬀerential
diagnosis. Immunohistochemistry is somewhat less reliable,
since viral proteins such as LMP1, LMP2, EBNA1, and
EBNA2 may be expressed focally or inconsistently in PTLD
cases with EBV infection [78].
EBV load testing is commonly used to assist in diagnosis
and monitoring of transplant recipients, despite a paucity of
clinical trials demonstrating the utility of EBV DNA meas-
urement in such settings. Indications for EBV load testing in
an immunosuppressed transplant recipient typically include
lymphadenopathy or other mass lesion, organ dysfunction,
fever, malaise, or other signs and symptoms suggestive of
PTLD. In addition, routine monitoring of EBV load in high-
risk patients can help identify PTLD before signs and symp-
toms appear [79, 80]. An EBV load above the laboratory’s
established threshold for PTLD should be conveyed to the
clinician immediately so it may trigger a search for putative
sites of disease followed by biopsy, when reasonable, to
establish a histopathologic diagnosis. Even in the absence
of biopsy-diagnosed PTLD, preemptive intervention may be8 The Scientiﬁc World Journal
used to resolve laboratory-detected disease [71]. Preemptive
therapy may include reducing immunosuppression and in-
fusing anti-CD20 antibody or donor T cells. Patients at high
risk for PTLD (e.g., those who are intensely immunosup-
pressed and who were seronegative at the time of transplant)
tend to be monitored frequently (e.g., weekly in the ﬁrst
few months after transplant and then monthly) so that pre-
emptive therapy may be considered [71, 81]. Optimally
designed trials should measure EBV load once monthly
during the ﬁrst year, with some patients continuing to be
frequently monitored beyond the ﬁrst year if they have a
history of high EBV loads, if their drug regimen is particu-
larly immunosuppressive, or in the aftermath of discontinu-
ing antiviral prophylaxis. The European Best Practice Guide-
lines for Renal Transplantation recommend using EBV load
to gauge intervention [73]. In its practice guidelines, the
“Kidney Disease: Improving Global Outcomes” Transplant
Work Group recommends that high-risk renal transplant
patients be tested for EBV nucleic acid once within the ﬁrst
weekaftertransplant,thenatleastmonthlyfor3to6months,
and then every 3 months for the rest of the ﬁrst year. Addi-
tional EBV testing is recommended after treatment for acute
rejection [82].
Clinical management of PTLD typically involves reduc-
ing iatrogenic immunosuppression so that natural immunity
against EBV and the neoplastic clone is restored [71, 82].
Complementary interventions include infusing donor lym-
phocytes, infusing EBV-speciﬁc cytotoxic T cells that are
grownexvivobyexposingHLA-matchedTcellstoEBVanti-
gens [83–85] and infusing anti-CD20 monoclonal antibody
(e.g., rituximab) [86–88]. If initial intervention is insuﬃ-
cient, more traditional cancer treatment with radiation and
multidrug chemotherapy is used [72].
Antiviral therapy with acyclovir or ganciclovir remains
controversial as these agents are not active against the latent
form of EBV found in PTLD. Outcomes with PTLD in renal
transplant recipients vary depending on the site of involve-
ment. Patients with isolated allograft involvement have a
ﬁve-year survival of approximately 68% compared with
thosepatientswithPTLDextendingbeyondthetransplanted
kidney whose ﬁve-year survival varied between 36 and 38
percent [89].
6. HumanHerpesvirus6,HumanHerpesvirus7,
andHumanHerpesvirus8
Human herpesvirus 6 and human herpesvirus 7 (HHV 6
and HHV 7) belong to subfamily Betaherpesvirinae, genus
Roseolovirus, species Human herpesvirus 6 and human
herpesvirus 7. Both viruses are ubiquitous with a high sero-
prevalence in adults. After primary infection, these viruses
establish a latent or persistent infection that remains for the
lifetime of the host. The viruses are lymphotropic, but HHV
6 in particular, which uses the CD46 molecule as its recept-
or, may also infect other cell types, such as monocytes and
epithelial and endothelial cells. HHV-6 isolates are classi-
ﬁed into two variants (termed HHV 6A and HHV 6B)
on the basis of distinct genetic, antigenic, and biological
characteristics. The speciﬁc pathogenicity of each variant re-
mains poorly understood [90, 91]. Most infections in renal
transplant recipients are due to HHV 6B. HHV7 uses
the CD4 molecule as its receptor and is more strictly
lymphotropic.The stimulus for reactivation of beta-her-
pesviruses in renal transplant recipients is an immunosup-
pressiveregimen.Inaddition,thesevirusespossessimmuno-
modulating properties, including the ability to alter the
expression of immune activation molecules, modulate ex-
pression of several cytokines and chemokines and induce
apoptosis in lymphocytes, which may contribute to immu-
nosuppression. Productive infection of CD4 T cells results in
cytopathic eﬀects and cell destruction [92]. The ubiquitous
nature of HHV 6 and HHV 7 creates conditions for the
development of concurrent infection and interaction be-
tween these viruses. The kinetics of the activation of these
viruses during the posttransplantation period suggest that
HHV 7 may act as a cofactor for HHV 6 and CMV reac-
tivation, while both HHV 6 and HHV 7 may act as cofactors
in the pathogenesis of CMV disease and acute rejection
[4, 5, 11]
HHV 6 has been associated with fever, rash, encephalitis,
hepatitis, myelosuppression, and interstitial pneumonitis
[93]. Diagnoses of HHV 6 and HHV 7 infections are made
by qualitative and quantitative molecular assays, by tissue
immunohistochemistry, and/or peripheral blood mononu-
clear cell culture. Treatment is similar to CMV and should
involve reduction of immunosuppression and ganciclovir,
but cidofovir and foscarnet have also been utilized [11].
Human herpesvirus 8 (HHV 8) belongs to subfamily
Gammaherpesvirinae, genus Rhadinovirus, species Human
herpesvirus 8. HHV 8 has been associated with Kaposi’s Sar-
coma, primary eﬀusive lymphoma, and Multicentric Castle-
man’s Disease (lymphoproliferative disorder). Infection in
the renal transplant population is thought to most com-
monly happen through reactivation of latent virus, although
primary infection after transplant can occur and can be
acquired through the allograft itself [94]. Transplantation-
associated Kaposi’s Sarcoma occurs in 0.2 to 5% of renal
transplant recipients, varying by ethnic group and immuno-
suppressive regimen [95–97]. Of all of the tumors in
solid-organ transplantation, Kaposi’s Sarcoma occurs at the
shortestintervalaftertransplant.HHV8isthoughttoleadto
Kaposi’s Sarcoma through upregulation of vascular endothe-
lial growth factor (VEGF) receptor Flk1/KDR in endothelial
cells [98]. Therapy for Kaposi’s Sarcoma includes reduc-
tion of immunosuppression and cytotoxic chemotherapy.
Sirolimus (rapamycin), an immunosuppressive drug used
in kidney-transplant recipients, probably has antineoplastic
eﬀects. The immunosuppressive and antineoplastic eﬀects of
sirolimus may be due to a common mechanism [98–101].
It is thought that sirolimus inhibits not only production of
VEGF but also dampens its eﬀects on endothelial cells, and
it has been suggested that sirolimus inhibits the progression
of Kaposi’s sarcoma in kidney-transplant recipients while ex-
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7.BK andJC Virus
BK polyomavirus (BKV), JC polyomavirus (JCV), and
Simian virus belong to family Polyomaviridae,g e n u sP o l y -
omavirus.Inthelast10years,improvedimmunosuppression
drugs have decreased the rates of acute rejection in kidney
transplantation but have also led to the emergence of poly-
omavirus-associated nephropathy (PVAN). This occurs in
1% to 10% of patients with kidney transplantation and is
caused by BK virus in more than 95% of cases. Less than 5%
of cases are attributed to the JC virus. Initially, lack of re-
cognition or late diagnosis of PVAN resulted in rapid loss of
graft function in more than 50% of patients [102, 103].
Serological evidence of past BKV exposure has been seen
to reach 90% in adolescents and adults around the world and
seems not to have changed since the ﬁrst discovery of BKV
in the 1970s. Similar to earlier studies, Hirsch et al. [104]
found 80% seropositivity in a prospective study of patients
with kidney transplantation. Accordingly, mismatched BKV
serostatus between donor graft and recipient is signiﬁcantly
less frequent than cytomegalovirus mismatches and, in the
absence of change, cannot explain the emergence of PVAN in
the last decade. However, higher BKV antibody titers in kid-
ney donors and lower titers in recipients have been identiﬁed
as risk factors for BKV replication and viremia posttrans-
plantation [102]. The recent increase in BK infections has
been attributed, in part, to the use of more potent immuno-
suppressiveregimens.However,nospeciﬁcimmunosuppres-
sant medication or combination has been demonstrated to
increase the risk of nephropathy. Caucasian race, cadaveric
renal transplant, older age, presence of diabetes, and com-
bined kidney and pancreas transplants have all been shown
to be associated with BK virus nephropathy [105].
Primary infections with BKV and JCV are typically sub-
clinical or linked to mild respiratory illness and are followed
by viral dissemination to the sites of lifelong persistent infec-
tion. The major sites of persistence for both BKV and JCV
are the cells of the kidney and urinary tract [106]. BKV DNA
has been found in 30 to 50% of normal kidney tissues, with
distribution patterns of small foci throughout the cortex and
medulla, and in 40% of ureters. JCV DNA can be detected in
approximately 10 to 50% of normal kidney samples [106].
Reactivation of latent virus has been reported in old age,
pregnancy, and diabetes mellitus, and immunosuppression
associated with congenital immunodeﬁciency, organ trans-
plantation,orHIVinfection.Themoststriking featureofBK
infection in kidney transplant recipients is the lack of fever,
malaise, myalgias, leukopenia, anemia, thrombocytopenia,
or other symptoms or signs typical of viral infection, despite
viral loads exceeding a billion copies/mL in the urine or
100000 copies/mL in the blood [107]. BKV nephropathy
presents with renal dysfunction without other clinical signs
or symptoms.
Although JC virus has been rarely implicated as a cause
of nephropathy either alone or in combination with BK, it
is more commonly seen as a cause of Progressive Multifocal
Leukoencephalopathy, a demyelinating process involving
the cerebral white matter. Presenting symptoms include
progressive neurologic impairment, which can progress to
dementia [108].
Laboratory monitoring strategies for BKV are still evolv-
ing. Quantitative nucleic acid-based viral load assay of urine
or blood are becoming widely used for BKV screening [107].
Detectable virus in the blood is more predictive of BKVN
than viruria alone. Some medical centers prefer urine cyto-
logyastheprimaryscreeningtechnique[109].Whileurinary
“decoy cells” have excellent sensitivity for the detection of
overt BKVN, polymerase chain reaction (PCR) is four times
more sensitive than urine cytology for monitoring asymp-
tomaticviruria[110].Additionally,PCRprovidesamoreob-
jective estimate of true viral load and can distinguish BK vir-
uria from JC viruria. JCV excretion in the urine is usually in-
signiﬁcant, although very rare cases of JCV associated inter-
stitial nephritis are on record. Decoy cells are not stable,
whereas DNA is, and PCR may be used for monitoring
of patients at a distance from the transplant center. The
relative costs of PCR versus cytology are a center-dependent
variable. Laboratory screening for BKV should certainly be
done for any unexplained rise in serum creatinine [107].
The cost of screening was found to be substantially oﬀset by
the savings related to reductions in immunosuppression fol-
lowing diagnosis of BKVN. No anti-viral agents were admin-
istered. Deﬁnitive diagnosis of BKVN requires a biopsy and
demonstration of BKV inclusions in tubular epithelial or
Bowman’s capsular epithelial cells. Viral infection is accom-
panied by varying degrees of inﬂammatory cell inﬁltrates,
tubular atrophy, and ﬁbrosis. The cytopathic eﬀect seen
by light microscopy is typical, but not pathognomonic for
BKVN. Conﬁrmatory immunohistochemistry or in situ hy-
bridization studies are usually performed using antibodies
against speciﬁc for BKV proteins or probes complementary
to viral DNA [103, 105, 107]. Electron microscopy can be
used to demonstrate unenveloped, viral particles, approxi-
mately 40nm in diameter. Since BKVN can be focal in dis-
tribution, ideally two biopsy cores should be examined. The
availability of medullary parenchyma increases the diagnos-
tic sensitivity. Negative biopsy results cannot rule out BKVN
with certainty, and a diagnosis of “presumptive BKVN” can
bemade if thereis renalallograftdysfunctionassociated with
BK viremia [107]. A deﬁnitive diagnosis of rejection con-
current with viral nephropathy should only be made if there
is endarteritis, ﬁbrinoid arterial necrosis, glomerulitis, or ac-
cumulation of the complement degradation product C4d
along peritubular capillaries.
BK and JC shedding have been reported to coexist in
16% of patients with decoy cells with the long-term pro-
gnosis of this ﬁnding being similar to that of patients with
pure BK shedding. Only a few published cases of PVAN have
been attributed to JC virus. In a cohort of patients screen-
ed for decoy cells, 27% were found to have JC (only) shed-
ding in the urine. These patients were older and showed
decoy cells appearing later compared with patients with pure
BK shedding [111]. Among these were six patients with
JCV-associated nephropathy, documented by positive cyto-
logy, positive plasma quantitative PCR, and positive SV40
staining. With decreasedimmunosuppression, many of these
patients continued to shed JCV. They all had stable serum10 The Scientiﬁc World Journal
creatinin,andtheonlyindicationforbiopsywasthepresence
of“decoy”cellsintheurine.Thesepatientsdidnothavegraft
dysfunction or loss. Progressive multifocal leukoencephalo-
pathy, a complication of JCV infection typically found in pa-
tients with HIV infection, has rarely been reported in renal
transplant recipients [109].
Reduction/adjustment in immunosuppression remains
the cornerstone for the treatment or prevention of PVAN
[102–105]. Because the reconstitution of the immune system
with control of the infection takes 4 to 12 weeks, it is imper-
ative to start treatment as early as possible [112]. The one
risk encountered with reduction in immunosuppression is
the development of acute rejection. The preliminary results
of Wali et al. [113] reﬂect the protocol used at the Uni-
versity of Maryland, which consists of intensive screening
with subsequent stepwise decrease in immunosuppression.
This protocol has resulted in clearance of Vm with no graft
loss or signiﬁcant rejection diagnosed. Speciﬁcally immuno-
suppression reduction is as follows: step 1, decrease in the
dose of MMF by 50% immediately after diagnosis; step 2,
50% decrease in the target trough level of tacrolimus at 3
months if decoy cells persisted; and step 3, elimination of
MMF at 6 months if decoy cells persisted. Maintenance dual
therapy consisted of the modiﬁed dose of tacrolimus and
maintenance dose of prednisone (not exceeding 7.5 to 15mg
per week). In addition to decrease in immunosuppression,
several centers have reported the use of several antipolyoma-
viral agents, with anti-BKV activity in vitro. These include
cidofovir, leﬂunomide, quinolones, and intravenous immu-
noglobulin [102, 105, 114]. None of these agents have
been approved by the Food and Drug Administration for
PVAN treatment. However, they have been used empirically,
and in many cases at advanced stages of the disease when
graft dysfunction persists or worsens. The eﬃcacy of these
a n t i v i r a la g e n t si sd i ﬃcult to determine, as they have been
used in combination with reduction in immunosuppression,
and even, in certain cases, in combination with each other.
In addition, no prospective, randomized control trials have
been conducted. In summary, examination of the available
literature demonstrates that none of the ancillary treatments
described has been conclusively proven to be eﬃcacious.
Most studies were neither randomized nor double-blinded,
and histologic grading of PVAN was often missing. In
addition, in many cases, renal dysfunction was present at the
time of diagnosis. Multicenter prospective studies are needed
to clarify this important issue stratifying histologic grading,
renal function, viral load diagnosis, and most importantly,
an evaluation of diﬀerent strategies assessed independent-
ly.
Early diagnosis with close monitoring of renal function
andserial determinations of Vm continue to represent the
most eﬃcacious tool to control PVAN. Systematic reduction
in immunosuppression has not been associated with clear
evidence of increased chronic rejection but longer times of
followup and more stringent studies are necessary to deter-
mine the longterm impact of the interventions for PVAN on
long-term graft outcomes.
8.HepatitisBandCVirus
Hepatitis B virus (HBV) belong to family Hepadnaviridae,
genus Orthohepadnavirus,species Hepatitis B virus. In pa-
tients with chronic kidney disease undergoing renal trans-
plantation, despite improved outcomes, liver disease has per-
sisted as an important cause of morbidity and mortality.
The prevalence of hepatitis B virus infection among patients
on renal replacement therapy has decreased because of the
implementation of preventive strategies in the dialysis popu-
lation [115, 116]. Currently, it is estimated the prevalence in
the hepatitis disease population ranges from 0.1 to 0.4 per-
cent [30]. Approximately 2 to 10 percent of patients with a
history of Hepatitis B before transplantation will reactivate
posttransplant. The most important factor inﬂuencing
HBsAg seropositive status in recipients is the acquisition of
HBV infection before renal transplantation and not via an
infected graft or the surgery itself [117]. In the era of in-
creasing emigration of people from high endemic area to
industrialized countries, HBV infection will remain a per-
sistent concern for public health authorities.
The impact of HBsAg seropositive status on patient sur-
vival after renal transplantation has been controversial [117].
Initial reports mostly focused on 5-year survival rates and
generally failed to show a diﬀerence between HBsAg-posi-
tive and -negative renal transplant patients. In contrast,
other studies of appropriate size and longer followup have
found an unfavorable eﬀect of HBsAg [116]. Mathurin and
colleagues reported that 10-year patient survival was signi-
ﬁcantly higher in noninfected (80% ± 3%) than in HBsAg-
positive recipients (55% ± 6%) or in recipients who were
anti-hepatitis C virus (HCV) positive (65% ± 5%) [118].
Multivariate analysis demonstrated that HBsAg was an in-
dependent factor associated with inferior patient survival at
10 years (P b.0001). Fabrizi and colleagues, in a subsequent
meta-analysis, showed that HBsAg seropositive status was an
independent risk factor for death [119].
Am o r er e c e n ts t u d yb yM a t o sa n dc o l l e a g u e sa t t e m p t e d
to identify factors that increase liver ﬁbrosis formation in
renal transplanted patients with HBV infection [120]. They
followed 55 patients for a mean time of 5 ± 4 years post-
transplant. Liver biopsies of post-renal transplantation with
advanced ﬁbrosis were compared with those with mild ﬁbro-
sis. Logistic regression analysis was applied to variables (age,
sex, estimated time since infection, history of renal trans-
plantation, donor type, ALT index, HBeAg, anti-HCV or
quantitative HBV DNA, post-RT time, and HBV-HCV coin-
fection).Sixty-sixpercentofpatientswereonacyclosporine-
based regimen. The only independent factor associated with
more advanced ﬁbrosis was increased length of time after
transplant. Immunosuppression postrenal transplantation
may augment HBV replication by a variety of mechanisms
including by diminishing activity of cytotoxic T lympho-
cytes. Azathioprine may stimulate intracellular HBV syn-
thesis. Furthermore, calcineurin inhibitors (CNIs) may have
direct eﬀects on HBV replication [116]. Reactivation of HBV
infection even in HBs Agseronegative individuals whose
serological proﬁle indicates remote, resolved HBV infection
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HBsAg in serum [117]. Newly recognized HBV infection
afterrenaltransplantationcanreﬂectdenovoinfectionorre-
activation of prior resolved infection. Some investigators ob-
served in renal transplanted recipients after transplantation
an increased replication with reappearance or increase in
s e r u mH B VD N Al e v e l sa n dH B e A ga sw e l la sr e a p p e a r a n c e
of serum HBsAg following apparent clearance of prior HBV
infection. Reactivation may cause necroinﬂammatory liver
injury with biochemical dysfunction. Recent cases of reac-
tivation of HBV after RT have been reported [121, 122], and
fulminant hepatic failure due to HBV reactivation has been
already noted after renal transplantation [123]. The 2 pro-
posed theories for viral reactivation after RT are as follows:
the ﬁrst hypothesis include “occult HBV infection” in the
RT candidate before transplant and viral replication of HBV
under the inﬂuence of immunosuppression. Another theory
is the loss of protective immunity and infection by a mutated
strain. Naturally occurring mutations in the preC region and
core promoter region are found in patients with long-stand-
ing chronic HBV infection [124]. Renal transplant recipients
are at increased risk of developing a variety of cancers. Hepa-
tocellular carcinoma is usually associated with viral hepatitis
(HBV and HCV) but has been reported in postrenal trans-
planted recipients without overt evidence of viral hepatitis,
cirrhosis, or metabolic liver disease [125].
Eﬀective and safe vaccines that contain HBsAg, initially
plasma derived and more recently manufactured by recom-
binant DNA technology, have been available since the early
1980s [126]. Vaccination against HBV is recommended for
all susceptible patients on dialysis (i.e., those having anti-
hepatitis B surface titers b10IU/mL). Patients on mainte-
nance dialysis have a suboptimal response (40%–50%) to
HBV vaccine compared with the general population (N95%
response). Several approaches have been tried to enhance
response rates to HBV vaccine in these patients. These have
included the administration of double or multiple doses of
HBV vaccine, intradermal administration of vaccine, and
vaccination with the simultaneous use of adjuvants (granu-
locyte macrophage-stimulating factor, thymopentin, ery-
thropoietin, zinc supplements, etc.). Current recommenda-
tions for HBV vaccination in susceptible dialysis patients are
administration of 4 double doses (40μg each dose) by in-
tramuscular route at 0, 1, 2, and 6 months [126].
Evaluation of the donor includes testing with suspected
HBV infection including HBsAg, HBsAb, and anti-HBc. The
risk of HBV transmission to the renal transplanted recipient
is a function of serologic status of both donor and recipient.
A donor with HBsAb-positive serology due to vaccination
will not transmit HBV infection. A donor with isolated anti-
HBc-positive serology should have further serologic testing
donetodiﬀerentiateacuteinfectionorremoteexposure.Ifan
IgM anticore is detected, the patient may have a recent acute
HBV infection and should not be used in an HBV naive re-
cipient without antiviral prophylaxis. Although livers har-
vested from isolated anti-HBc positive donors have a consid-
erable risk of HBV transmission to recipients of liver grafts,
kidneys from the same donors carry a low risk of trans-
mission [127]. Kidneys from HBsAg-positive donors have a
higher risk of transmitting HBV infection to their recipients,
and the risk of transmission is greater if the donor status is
HBsAg positive along with being HBeAg positive. HBsAb-
positive recipients should not require prophylaxis [116].
On the other hand, organs from HBsAg-positive donors
can be used in HBcAb-positive/HBsAb-positive recipients
while requiring lamivudine prophylaxis (1 year). There are
6 licensed drugs available for the treatment of chronic HBV
(interferon, lamivudine, adefovir, entecavir, telbivudine, and
tenofovir). To date, interferon has not been promising in the
management of HBV in renal transplanted recipients. There
have been no studies regarding the use of telbivudine and
tenofovir after renal transplantation. However, the manage-
ment of HBV after renal transplantation has given encourag-
ing results with lamivudine, adefovir, and entecavir [116].
TheroleofliverbiopsyintheevaluationofRTcandidates
with HBsAg is important because it is diﬃcult, on clinical
groundsalone,toestimatetheseverityofliverdiseaseinCKD
population. Patients with established cirrhosis on liver bio-
psy are at risk for hepatic decompensation after isolated RT,
and kidney transplantation alone is contraindicated. In pa-
tients with normal renal function, antiviral therapy has been
reported to lead to regression of advanced histologic lesions.
Similar to hepatitis B, hepatitis C is a complex problem
for the renal transplant recipient. Hepatitis C virus belongs
to family Flaviviridae, genus Hepacivirus, species Hepatitis C
virus Incidence rates in the chronic disease population have
decreased, averaging 0.7 to 3 percent per year [30]. Recog-
nition of hepatitis C in patients with chronic renal failure
may be confounded by the limited sensitivity of serologic
diagnosis in this population. All hepatitis C seronegative
transplant candidates who have abnormal transaminases
and/or risk factors for hepatitis C should undergo nucleic
acid testing. Because of the increased risk of progressive liver
disease following transplantation, patients with hepatitis
C should undergo liver biopsy to exclude advanced liver
disease, which in some cases may necessitate a combined
liver-kidney transplant [128]. Hepatitis-C-positive patients
usually have a marked rise in viral load with initiation of im-
munosuppression immediately after transplant. Chronic
immunosuppression used in transplant recipients also leads
to higher circulating levels of virus and intrahepatic virus
due to the decreased T-cell response to the NS3 region of
hepatitis C virus [30]. Consequently patients with hepatitis
C are at increased risk for progressive liver disease and the
development of cirrhosis following transplantation.
Because of the large demand for organs, consideration
has been given to the use of hepatitis-C-positive donors.
Transplant recipients may acquire hepatitis C through trans-
plantation itself, which may lead to severe hepatitis. Al-
though recipients of HCV positive kidneys have diminished
patient and graft survival as compared with recipients of
HCV-negative kidneys, survival may be improved when
compared with survival on dialysis [129].
The problem of anti-HCV therapy is that interferon
(IFN) has been associated with an increased risk of allograft
rejection not only in the functioning grafts but also in
the already failed grafts [130]. Therefore this may explain
the major hesitancy to the use of IFNa in renal transplant
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expression, increased cell surface expression of HLA anti-
gens, and enhanced function of natural killer cells, cytotoxic
T cells, and monocytes. These immune-stimulant eﬀects can
resultinenhancedallograftrejection—whichmaybeirrever-
sible—even in patients with stable grafts. So it has been
indicated only in patients with ﬁbrosing cholestatic hepatitis
or other conditions in which the beneﬁts of treatment out-
weigh the risk of allograft loss [131]. There are extremely
limited data evaluating the eﬃcacy and complications of
IFNa therapy in the treatment of possible HCV-related cry-
oglobulinemia or de novo or recurrent glomerular disease in
renal transplant recipients. Pageaux et al. [132] showed that
treatment of HCV with IFN after transplantation might not
be as risky as initially shown. Posttransplant monotherapies
with ribavirin and/or amantadine have no apparent impact
on HCV viremia or liver histology [133]. So the best strategy
is to treat HCV infection in patients on dialysis before trans-
plantation afterexcluding cirrhosis by liver biopsy andif pre-
sent patients should be considered for combined kidney-
livertransplantation[128,132,133].Suchstrategycouldpre-
vent liver disease progression and even HCV-related mor-
bidities such as glomerulonephritis and posttransplant dia-
betes mellitus.
9. Human Immunodeﬁciency Virus
Human immunodeﬁciency virus (HIV) belong to family
Retroviridae, genus Lentivirus, species Human immunodeﬁ-
ciency virus. HIV infection has been a major global health
problem for almost three decades. With the introduction
of highly active antiretroviral therapy (HAART) in 1996,
and the advent of eﬀective prophylaxis and management
of opportunistic infections, AIDS mortality has decreased
markedly. In developed countries, this once fatal infection is
now being treated as a chronic condition. As a result, rate of
morbidityandmortalityfromothermedicalconditionslead-
ing to end-stage liver, kidney, and heart disease is steadily in-
creasing in individuals with HIV. Renal diseases directly
related to HIV infection include HIV-associated nephropa-
thy (HIVAN), immune complex diseases, and thrombotic
microangiopathy [134]. Although the widespread use of
HAARThasdecreasedtheincidenceofHIV-relatedrenaldis-
ease, the overall prevalence of renal disease continues to in-
crease among patients with HIV. The most aggressive HIV-
related renal disease is HIVAN, which occurs in approxi-
mately 10% of patients with HIV [135]. These patients can
progress to end-stage renal disease (ESRD) within weeks to
months.
Recent studies conﬁrm that outcome of renal transplan-
tation in adequately selected HIV-infected patients receiving
kidneys from HIV-negative donors is similar to that of HIV-
negative RT recipients [136]. Main challenges in the clinical
management of HIV-infected RT recipients are the pharma-
cologic interactions between immunosuppressive agents and
some classes of antiretroviral drugs and a higher rate of acute
rejection in comparison with HIV-negative RT recipients.
Currently, organ transplantation from HIV-infected donors
is an absolute contraindication in Western countries but
its potential utility is under consideration [137]R e c e n t l y ,
Muller et al. [138] reported the outcome of four HIV-infect-
ed RT recipients who received their grafts from two HIV-
infected donors in South Africa, being the ﬁrst clinical
experience published involving this type of transplants. After
12 months of followup, all recipients had a functioning renal
allograft with a good renal function, and HIV infection
wascontrolledunderdiﬀerentantiretroviralregimens.South
Africa is a country with a high HIV prevalence in the general
population, and HIV infection is an absolute exclusion cri-
terion for access to dialysis or RT. Muller et al. [138] sug-
gestedthattheuseofHIV-infecteddonorswouldincreasethe
donor pool, providing renal allografts to HIV-infected pa-
tients otherwise sentenced to death as a consequence of end-
stage renal disease. Deceased HIV-infected patients represent
a potential of approximately 500–600 donors per year for
HIV-infected transplant candidates. In the current era of
HIV management, a legal ban on the use of these organs
seems unwarranted and likely harmful [139].
HIV-infected patients receiving renal transplants may be
at higher risk of acute rejection (up to 25%) and the opti-
mal management of immunosuppression in HIV-infected
individuals remains unknown [140]. Treatment of rejection
with cytolytic agents such as thymoglobulin may result in
prolonged depression of CD4 counts and signiﬁcant in-
fection-related morbidity [141]. The risks of antilymphocyte
therapy should be balanced with the risks for rejection in
HIV-infected recipients.
10. Respiratory Viruses
Various viruses can cause respiratory disease in the renal
transplant population, including adenovirus, respiratory
syncytial virus, inﬂuenza, parainﬂuenza, human metapneu-
movirus,rhinovirus,andcoronavirus[30].Thesevirusescan
lead to upper respiratory tract disease, as well as bronchitis,
pneumonitis, and pneumonia. Adenovirus can cause a mu-
ltitude of complications including gastroenteritis, cystitis,
and necrotizing hepatitis in addition to respiratory illness. In
immunocompromised patients, adenovirus infections tend
to be more prolonged, more severe, and sometimes fatal.
They may occur due to endogenous reactivation or primary
infection. Coinfection with more than one adenovirus sero-
type per clinical event was more frequent in immunocom-
promised patients (30%) than in immunocompetent pa-
tients (5%) [142]. Clinical manifestations in immunocom-
promised patients include pneumonia, hepatitis, hemor-
rhagic cystitis, colitis, pancreatitis, meningoencephalitis, and
disseminated disease, depending on the underlying disease,
aﬀected organ system, patient age, and virus serotype. In
the renal transplant recipient, adenovirus can also cause
nephritis, which presents with fever, renal dysfunction and
liver function test abnormalities [143, 144]. Infection with
respiratory viruses may also be associated with rejection.
Severityofdiseaseisgreatestinthosewhohavebeenmorere-
cently transplanted or are more immunosuppressed.
Clinicians and pathologists should be vigilant and aware
of AV nephritis in renal allografts. Diagnosis can be diﬃcult.
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Multiple diagnostic modalities, including immunohisto-
chemistry of biopsy material, serology, viral cultures, and
viral gene PCR may be required to make the diagnosis. Path-
ological clues to the diagnosis of AV infection include gross
haematuria, often severe, with haemorrhagic cystitis and
fever with or without pneumonitis. On renal biopsy, the pre-
sence of tubulointerstitial necrosis, haemorrhage, and atyp-
ical “smudged” epithelial cells can be helpful in recognizing
the lesion. Although most AV infections occur within weeks
or months of transplantation due to activation of a latent in-
fection, AV infection can also uncommonly occur years later.
This may be due to a de novo AV infection [144].
Prevention involves avoidance of other individuals who
have signs or symptoms of infection, hand hygiene, and use
of droplet precautions for those suspected of having infec-
tion. Inﬂuenza vaccine should be administered before trans-
plant and every year after transplant, although administra-
tion should not be given in the early posttransplant period
becauseofespeciallyreducedvaccineresponses[30].Because
the vaccine may be insuﬃciently protective in the patient
after transplant, the inﬂuenza vaccine should also be admin-
istered to the patient’s family members and to health care
providerstodecreasepossibleriskoftransmission.Intranasal
inﬂuenza vaccine should not be used, as it is utilizes live
virus [20]. Morelon et al. [145] suggest that intradermal in-
ﬂuenzavaccinationmayoﬀerenhancedimmunogenicityand
protection in persons who do not respond well to conven-
tional trivalent inactivated inﬂuenza vaccine. Further studies
should be conducted in immunocompromised populations
to validate the trends for higher eﬃcacy of ID versus con-
ventional route of immunization against inﬂuenza.
Treatment of respiratory viral infections involves sup-
portive care and, in some cases, the use of antiviral medica-
tions.Inﬂuenzacanbetreatedwithoseltamivirorzanamavir,
which will treat both inﬂuenza A and B. Amantadine is not
recommended because it treats inﬂuenza A only and increas-
ing rates of resistance have been seen in inﬂuenza A. Rib-
avirin is approved to treat lower respiratory infection with
respiratory syncytial virus; however actual clinical eﬃcacy
has not been proven. Severe adenovirus infections are usual-
ly treated with reduction of immunosuppression. Anecdotal
reports suggest that cidofovir may have activity against aden-
ovirus, but its use must be balanced with the associated risk
of nephrotoxicity [146, 147].
11. West Nile Virus
West Nile virus (WNV) belong to family Flaviviridae, genus
Flavivirus, species West Nile virus. Since its isolation in
Uganda in 1937, WNV has been responsible for thousands
of cases of morbidity and mortality in birds, horses, and
humans. Historically, epidemics were localized to Europe,
Africa, the Middle East, and parts of Asia, and primarily
caused a mild febrile illness in humans. However, in the late
1990s, the virus became more virulent and expanded its geo-
graphical range to North America. In humans, the clinical
presentationrangesfromasymptomatic(approximately80%
of infections) to encephalitis/paralysis and death (less than
1% of infections) [148].
WNV was recently transmitted from one donor (likely
related to a blood transfusion) to multiple recipients [149].
Transplant recipients are at higher risk than the general
population for meningoencephalitis after exposure. In WNV
endemic regions, donors should be tested for WNV. Virus
from their donors have increased morbidity and mortality
[150, 151]. Recipients who acquire West Nile later in the
transplant course have more variable outcomes. To prevent
infection, seasonal screening should be considered for do-
nors before transplant by serologic and/or nucleic acid test-
ing. Treatment for West Nile in transplant recipients has not
been standardized but should include a reduction in im-
munosuppression along with supportive care [151]. Wheth-
er there is a role for hyperimmune globulin in transplant re-
cipientsiscurrentlyunknown.Viralinfectionsinrenaltrans-
plant patients continue to have signiﬁcant impact on patient
outcomes.Althoughpreventivemeasureshaveimproved,the
impact of newer immunosuppressive strategies continues to
promote the development of severe viral infections [20]. The
presence of new and emerging viral infections that may be
transmitted by transplantation, such as West Nile virus, will
likely present many future challenges for physician treating
transplant recipients.
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